Arcutis Biotherapeutics (ARQT) News Today $9.26 -0.67 (-6.75%) (As of 11/15/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Arcutis Biotherapeutics: +200% On ZORYVE Approval, But When Is The Next Leg Up?November 15 at 9:08 AM | seekingalpha.comTerrie Curran Sells 8,687 Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) StockNovember 14 at 8:56 AM | insidertrades.comArcutis’ ZORYVE® (roflumilast) Awarded Best Eczema Treatment by GlamourNovember 14 at 6:58 AM | markets.businessinsider.comTD Cowen Sticks to Their Buy Rating for Arcutis Biotherapeutics (ARQT)November 12, 2024 | markets.businessinsider.comGSA Capital Partners LLP Purchases 208,599 Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)GSA Capital Partners LLP increased its holdings in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) by 730.0% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 237,174 shares of the company's stock after pNovember 12, 2024 | marketbeat.comArcutis Biotherapeutics: Strong Financial Outlook and Strategic Growth Justify Buy Rating and $19 Price TargetNovember 9, 2024 | markets.businessinsider.comArcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Q3 2024 Earnings Call TranscriptNovember 8, 2024 | msn.comArcutis Biotherapeutics Reports Strong Q3 2024 ResultsNovember 8, 2024 | markets.businessinsider.comArcutis Biotherapeutics: Strong Q3 Performance and Strategic Growth Drive Buy RatingNovember 8, 2024 | markets.businessinsider.comArcutis Biotherapeutics Inc (ARQT) Q3 2024 Earnings Call Highlights: Robust Growth and ...November 8, 2024 | finance.yahoo.comArcutis Biotherapeutics (NASDAQ:ARQT) Receives Buy Rating from Needham & Company LLCNeedham & Company LLC restated a "buy" rating and issued a $18.00 target price on shares of Arcutis Biotherapeutics in a research note on Thursday.November 7, 2024 | marketbeat.comArcutis Biotherapeutics, Inc. (ARQT) Q3 2024 Earnings Call TranscriptNovember 7, 2024 | seekingalpha.comArcutis Biotherapeutics: Strong Commercial Execution and Strategic Growth Initiatives Justify Buy RatingNovember 7, 2024 | markets.businessinsider.comArcutis Announces Third Quarter 2024 Financial Results and Provides Business UpdateNovember 6, 2024 | globenewswire.comEarnings To Watch: Arcutis Biotherapeutics Inc (ARQT) Reports Q3 2024 ResultNovember 6, 2024 | finance.yahoo.comMasaru Matsuda Sells 5,015 Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) StockNovember 6, 2024 | insidertrades.comArcutis Biotherapeutics: Resilient Growth and Market Penetration Drive Buy RatingNovember 5, 2024 | markets.businessinsider.comArcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)November 4, 2024 | globenewswire.comabrdn plc Boosts Stake in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)abrdn plc increased its holdings in shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) by 223.8% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 482,074 shares of the company's stock after acquiringNovember 4, 2024 | marketbeat.comArcutis Biotherapeutics (NASDAQ:ARQT) Stock Price Up 8.7% - Here's What HappenedArcutis Biotherapeutics (NASDAQ:ARQT) Trading Up 8.7% - Should You Buy?November 1, 2024 | marketbeat.comAMI Asset Management Corp Buys 59,487 Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)AMI Asset Management Corp lifted its stake in shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) by 36.2% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 223,681 shares ofOctober 30, 2024 | marketbeat.comArcutis Biotherapeutics announces new patient-reported data on ZORYVEOctober 24, 2024 | markets.businessinsider.comBuy Rating Reaffirmed for Arcutis Biotherapeutics Amid Temporary Challenges and Strong Zoryve Sales ForecastOctober 23, 2024 | markets.businessinsider.comArcutis to Report Third Quarter 2024 Financial Results and Participate in an Upcoming Investor ConferenceOctober 23, 2024 | globenewswire.comHealth Canada approves Arcutis’ ZORYVE foam for seborrheic dermatitisOctober 22, 2024 | finance.yahoo.comArcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Receives Average Recommendation of "Moderate Buy" from AnalystsShares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Get Free Report) have been assigned an average rating of "Moderate Buy" from the seven ratings firms that are currently covering the stock, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold rating and fOctober 22, 2024 | marketbeat.comArcutis Canada Announces Health Canada Approval of ZORYVE® Foam to Treat Seborrheic Dermatitis in Individuals 9 Years of Age and OlderOctober 21, 2024 | ca.finance.yahoo.comSG Americas Securities LLC Trims Stock Position in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)SG Americas Securities LLC cut its stake in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) by 61.3% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 38,333 shares of the company's stock after seOctober 19, 2024 | marketbeat.comArcutis Biotherapeutics (NASDAQ:ARQT) Trading Down 3.2% - Should You Sell?Arcutis Biotherapeutics (NASDAQ:ARQT) Stock Price Down 3.2% - Should You Sell?October 18, 2024 | marketbeat.comArcutis Announces Health Canada Approval of ZORYVE® (Roflumilast) Foam 0.3% to Treat Seborrheic Dermatitis in Individuals 9 Years of Age and OlderOctober 18, 2024 | globenewswire.comWesbanco Bank Inc. Invests $955,000 in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)Wesbanco Bank Inc. acquired a new position in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 102,700 shares of the compaOctober 16, 2024 | marketbeat.comShort Interest in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Rises By 9.1%Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Get Free Report) saw a significant increase in short interest in September. As of September 30th, there was short interest totalling 27,130,000 shares, an increase of 9.1% from the September 15th total of 24,860,000 shares. Based on an average daily trading volume, of 2,140,000 shares, the short-interest ratio is presently 12.7 days.October 15, 2024 | marketbeat.comArcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Stake Boosted by Millennium Management LLCMillennium Management LLC increased its holdings in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) by 35.3% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 512,696 shares of the company's sOctober 13, 2024 | marketbeat.comArcutis Biotherapeutics, Inc (ARQT): A Small-Cap Leader in Skin Disease TreatmentsOctober 12, 2024 | msn.comARQT Arcutis Biotherapeutics, Inc.October 11, 2024 | seekingalpha.comArcutis Biotherapeutics (NASDAQ:ARQT) Trading Down 3.6% - Here's What HappenedArcutis Biotherapeutics (NASDAQ:ARQT) Stock Price Down 3.6% - Should You Sell?October 11, 2024 | marketbeat.comArcutis Biotherapeutics (NASDAQ:ARQT) Stock Quotes, Forecast and News SummaryOctober 10, 2024 | benzinga.comZoryve Drives Revenue Growth at Arcutis Biotherapeutics, Inc. (ARQT)October 9, 2024 | msn.comAQR Capital Management LLC Acquires 226,258 Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)AQR Capital Management LLC grew its holdings in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) by 727.5% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 257,357 shares of the company's sOctober 9, 2024 | marketbeat.comHsbc Holdings PLC Sells 492,187 Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)Hsbc Holdings PLC cut its stake in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) by 97.2% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 14,099 shares of the company's stock after selling 492,187 shaOctober 7, 2024 | marketbeat.comArcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 4, 2024 | globenewswire.comInsider Selling: Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) SVP Sells 3,725 Shares of StockOctober 4, 2024 | insidertrades.comInsider Selling: Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) SVP Sells $37,287.25 in StockArcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Get Free Report) SVP Larry Todd Edwards sold 3,725 shares of the company's stock in a transaction on Wednesday, October 2nd. The stock was sold at an average price of $10.01, for a total transaction of $37,287.25. Following the transaction, the senior vice president now owns 136,635 shares of the company's stock, valued at $1,367,716.35. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.October 3, 2024 | marketbeat.comArcutis Biotherapeutics (NASDAQ:ARQT) Stock Price Up 6.5%Arcutis Biotherapeutics (NASDAQ:ARQT) Shares Up 6.5%October 2, 2024 | marketbeat.comPerceptive Advisors LLC Boosts Position in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)Perceptive Advisors LLC increased its position in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) by 107.8% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,558,500 shares of the company's stock after buyingSeptember 30, 2024 | marketbeat.comArcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Given Consensus Rating of "Moderate Buy" by AnalystsArcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the seven ratings firms that are covering the firm, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation and five have aSeptember 27, 2024 | marketbeat.comArcutis Biotherapeutics, Inc. (NASDAQ:ARQT) CFO David Joseph Topper Sells 11,626 SharesSeptember 26, 2024 | insidertrades.comProfund Advisors LLC Has $448,000 Position in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)Profund Advisors LLC decreased its stake in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) by 61.8% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 48,190 shares of the company's stSeptember 26, 2024 | marketbeat.comArcutis : ZORYVE Cream 0.15% Improves Atopic Dermatitis Across Skin Types In Phase 3 TrialsSeptember 25, 2024 | markets.businessinsider.comNew Data Shows ZORYVE® (Roflumilast) Cream 0.15% Provided Consistent Improvement of Atopic Dermatitis in Individuals With Diverse Skin TypesSeptember 25, 2024 | globenewswire.com Get Arcutis Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ARQT and its competitors with MarketBeat's FREE daily newsletter. Email Address Has Trump Finally Gone Too Far? (Ad)Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news. Register For The Webinar To Discover ARQT Media Mentions By Week ARQT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ARQT News Sentiment▼1.020.56▲Average Medical News Sentiment ARQT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ARQT Articles This Week▼75▲ARQT Articles Average Week Get Arcutis Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ARQT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies INVA News Today PHAT News Today KNSA News Today OCUL News Today ORIC News Today SUPN News Today NKTX News Today KPTI News Today BTAI News Today BHVN News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ARQT) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcutis Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arcutis Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ARQT Stock Alerts